Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR1 | O14842 | 15/20 | 1.00 |
| ▸ | PPARD | Q03181 | 8/20 | 0.67 |
| ▸ | PPARA | Q07869 | 5/20 | 0.67 |
| ▸ | PPARG | P37231 | 4/20 | 0.67 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4860526 | 0.90 | FFAR1 (0.81) | FFAR1PPARDPPARAPPARG | |
| SCHEMBL4858508 | 0.87 | FFAR1 (0.77) | FFAR1PPARDPPARAPPARG | |
| SCHEMBL6238582 | 0.86 | FFAR1 (0.76) | FFAR1PPARDPPARAPPARG | |
| SCHEMBL3814837 | 0.82 | PPARD (0.78) | FFAR1PPARDPPARAPPARG | |
| SCHEMBL27650472 | 0.82 | FFAR1 (0.72) | FFAR1PPARDPPARAPPARG | |
| SCHEMBL4858253 | 0.82 | FFAR1 (0.69) | FFAR1PPARDPPARAPPARG | |
| SCHEMBL4858346 | 0.80 | FFAR1 (0.67) | FFAR1PPARDPPARAPPARG | |
| SCHEMBL4860828 | 0.79 | FFAR1 (0.65) | FFAR1PPARDPPARAPPARG | |
| SCHEMBL3740273 | 0.78 | FFAR1 (1.00) | FFAR1PPARDPPARAPPARG | |
| SCHEMBL3739526 | 0.78 | FFAR1 (1.00) | FFAR1PPARDPPARAPPARG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7345067-B2 | Aniline derivatives, their manufacture and use as pharmaceutical agents | HOFFMANN-LA ROCHE INC. (US) | 2008-03-18 | — | — | US | claimed |
| US-20040248951-A1 | Aniline derivatives, their manufacture and use as pharmaceuticals | F. HOFFMANN-LA ROCHE AG, A SWISS COMPANY (CH) | 2004-12-09 | — | — | US | claimed |
| US-7345067-B2 | Aniline derivatives, their manufacture and use as pharmaceutical agents | HOFFMANN-LA ROCHE INC. (US) | 2008-03-18 | — | — | US | disclosed |
| EP-1636198-A1 | ANILINE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2006-03-22 | — | — | EP | disclosed |
| WO-2004111020-A1 | ANILINE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2004-12-23 | — | — | WO | disclosed |
| US-20040248951-A1 | Aniline derivatives, their manufacture and use as pharmaceuticals | F. HOFFMANN-LA ROCHE AG, A SWISS COMPANY (CH) | 2004-12-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040248951-A1 | Aniline derivatives, their manufacture and use as pharmaceuticals | PPARA, PPARD, PPARG | FFAR1 24/4885PPARD 2/4885PPARA 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.